Corvus Pharmaceuticals (NASDAQ:CRVS) Given New $14.00 Price Target at Oppenheimer

Corvus Pharmaceuticals (NASDAQ:CRVS - Free Report) had its price target boosted by Oppenheimer from $8.00 to $14.00 in a report issued on Wednesday,Benzinga reports. Oppenheimer currently has an outperform rating on the stock.

Other equities research analysts have also recently issued research reports about the stock. Mizuho raised shares of Corvus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, October 22nd. StockNews.com lowered shares of Corvus Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Thursday, October 31st. Finally, LADENBURG THALM/SH SH boosted their price target on shares of Corvus Pharmaceuticals from $12.00 to $21.00 and gave the stock a "buy" rating in a research note on Monday, September 16th. One research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $12.83.

Corvus Pharmaceuticals Stock Up 2.1 %

Shares of NASDAQ CRVS traded up $0.18 during midday trading on Wednesday, reaching $8.87. 1,272,752 shares of the stock were exchanged, compared to its average volume of 358,239. The firm has a market cap of $554.82 million, a price-to-earnings ratio of -9.54 and a beta of 1.05. Corvus Pharmaceuticals has a twelve month low of $1.25 and a twelve month high of $10.00. The firm has a 50-day simple moving average of $6.66 and a two-hundred day simple moving average of $3.97.

Institutional Trading of Corvus Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Nwam LLC acquired a new position in shares of Corvus Pharmaceuticals in the 3rd quarter valued at approximately $53,000. Avity Investment Management Inc. grew its stake in shares of Corvus Pharmaceuticals by 138.2% in the third quarter. Avity Investment Management Inc. now owns 27,580 shares of the company's stock worth $146,000 after purchasing an additional 16,000 shares in the last quarter. Oppenheimer & Co. Inc. bought a new position in shares of Corvus Pharmaceuticals in the third quarter worth $89,000. Towerview LLC lifted its holdings in shares of Corvus Pharmaceuticals by 4.6% in the second quarter. Towerview LLC now owns 400,000 shares of the company's stock valued at $728,000 after buying an additional 17,500 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of Corvus Pharmaceuticals in the second quarter valued at $44,000. Institutional investors and hedge funds own 46.64% of the company's stock.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.